Immune correlates of protection for dengue: State of the art and research agenda.

Conference Paper

Dengue viruses (DENV1-4) are mosquito-borne flaviviruses estimated to cause up to ∼400 million infections and ∼100 million dengue cases each year. Factors that contribute to protection from and risk of dengue and severe dengue disease have been studied extensively but are still not fully understood. Results from Phase 3 vaccine efficacy trials have recently become available for one vaccine candidate, now licensed for use in several countries, and more Phase 2 and 3 studies of additional vaccine candidates are ongoing, making these issues all the more urgent and timely. At the "Summit on Dengue Immune Correlates of Protection", held in Annecy, France, on March 8-9, 2016, dengue experts from diverse fields came together to discuss the current understanding of the immune response to and protection from DENV infection and disease, identify key unanswered questions, discuss data on immune correlates and plans for comparison of results across assays/consortia, and propose a research agenda for investigation of dengue immune correlates, all in the context of both natural infection studies and vaccine trials.

Full Text

Duke Authors

Cited Authors

  • Katzelnick, LC; Harris, E; Participants in the Summit on Dengue Immune Correlates of Protection,

Published Date

  • August 24, 2017

Published In

Volume / Issue

  • 35 / 36

Start / End Page

  • 4659 - 4669

PubMed ID

  • 28757058

Pubmed Central ID

  • PMC5924688

Electronic International Standard Serial Number (EISSN)

  • 1873-2518

Digital Object Identifier (DOI)

  • 10.1016/j.vaccine.2017.07.045

Conference Location

  • Netherlands